NEW YORK ( TheStreet) -- DUSA Pharmaceuticals (Nasdaq: DUSA) hit a new 52-week high Wednesday as it is currently trading at $6.31, above its previous 52-week high of $6.14 with 270,886 shares traded as of 9:51 a.m. ET. Average volume has been 482,500 shares over the past 30 days. DUSA has a market cap of $141 million and is part of the health care sector and drugs industry. Shares are up 144.9% year to date as of the close of trading on Tuesday. DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. The company has a P/E ratio of 52.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
Practice your DUSA trading strategies and win cash in our stock game.
TheStreet Ratings rates DUSA as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full DUSA Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.